Atezolizumab (Tecentriq, Genentech) is an anti–PD-L1 monoclonal antibody indicated for the treatment of locally advanced or metastatic urothelial carcinoma and metastatic NSCLC. The drug is administered as an IV infusion. This section will describe the common adverse reactions associated with the drug, as well as warnings and precautions, drug interactions and other contraindications.
Common adverse reactions
Warnings and precautions
Drug interactions and other contraindications
Atezolizumab common adverse reactions
The most common reactions (≥ 20%) reported in patients with metastatic urothelial carcinoma treated with atezolizumab were fatigue, decreased appetite, nausea, urinary tract infection, fever and constipation.
Patients with metastatic NSCLC reported fatigue, decreased appetite, dyspnea, cough, nausea, musculoskeletal pain and constipation.
Atezolizumab warnings and precautions
Immune-mediated pneumonitis has been reported in patients receiving atezolizumab; patients should be monitored and treated with corticosteroids if pneumonitis is diagnosed.
Other immune-mediated adverse events include hepatitis, colitis, endocrinopathies (including hyperthyroidism, hypothyroidism, adrenal insufficiency and diabetes mellitus), pancreatitis and neuropathies. Infusion reactions have also occurred.
Atezolizumab drug interactions and other contraindications
Atezolizumab may cause fetal harm, and women of childbearing age should be counseled to use contraception during and for 5 months after the completion of atezolizumab treatment.